Anticancer drug (like Cisplatin) embedded in fucose-bound-carrier which is specific for the CA19-9 (fucosylated antigens) cancer cells produce
Original lipid nano particles(LNPs) with INF stimulator(Cyclic-di-GMP) showed dramatic activity as a cancer adjuvant.
Therapeutic response to PD-1/PD-L1 blockade can be predicted by using this biomarker expressing on cancer associated fibroblast (CAF)
Proteins/Peptides Can be Easily Functionalized
Against Peritoneal Dissemination, Lymph node/Liver metastases
Protection of active site by 2-nitroimidazole is released in hypoxia
DR6 mAb promotes Sdc1-DR6 dependent immunosuppressive pathway in autoreactive T cells
Inhibitor of Runx3 binding site on c-Myc promoter enable innovative anti-cancer therapy.
By using a novel, non-radioactive, chelate-forming compound.
Tyrosine kinase inhibitor(TKI) for drug-resistant EGFR mutant